This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
Avatar

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and EHA

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Kerry Rogers, Jennifer Woyach
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Kerry Rogers, Jennifer Woyach
176 views
June 21, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

12:42
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Liso-Cel in R/R MCL With Prior BTKi Thera…

Feat. L. Gordon
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
12:49
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options…

Feat. P. Johnson
View All

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
24:33
Indy Hematology Review

Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…

Feat. J. Woyach
25:47
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in Indolent B-Cell Lymphomas

Feat. J. Soumerai
08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

06:56
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…

Feat. M. Shadman
06:59
Constantine Tam

R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…

15:21
5th SOHO Italy Annual Conference

How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
08:45
Insights from 2023 ASH Annual Meeting

The Best of CLL: Highlights & Key Takeaways

Feat. V. Yazbeck
10:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…

Feat. J. Woyach
06:34
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…

Feat. A. Kittai
10:19
Alvaro Alencar

Pirtobrutinib in R/R CLL

20:58
Andrew Lipsky

CLL: Recent Updates on the Use of BTK Inhibitors

22:47
Indy Hematology Review

CLL: Evaluating and Therapeutic Approaches for the Management of the…

Feat. J. Woyach
06:21
City of Hope

Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL

Feat. A. Danilov
18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
05:12
Insights from 2023 ASH Annual Meeting

R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Vene…

Feat. N. Shah